{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T04:28:54Z","timestamp":1727324934187},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.nucmedbio.2024.108939","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:35:16Z","timestamp":1719966916000},"page":"108939","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Transcatheter pseudo-vascular isolation for localization and concentration of a large molecule theranostic probe into a transgenic OncoPIG kidney tumor"],"prefix":"10.1016","volume":"136-137","author":[{"given":"Samuel L.","family":"Rice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando G\u00f3mez","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamaal","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mhd Wisam","family":"Alnablsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108939_bb0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0169-5002(02)00357-4","article-title":"Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?","volume":"38","author":"Gridelli","year":"2002","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.nucmedbio.2024.108939_bb0010","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.1988.6.11.1746","article-title":"The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy","volume":"6","author":"Richardson","year":"1988","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108939_bb0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108939_bb0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-015-1208-y","article-title":"Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion","volume":"39","author":"de Baere","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"Supplement 2","key":"10.1016\/j.nucmedbio.2024.108939_bb0025","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.2967\/jnumed.116.187229","article-title":"Radioembolization of colorectal liver metastases: indications, technique, and outcomes","volume":"58","author":"Boas","year":"2017","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.nucmedbio.2024.108939_bb0030","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jvir.2023.06.028","article-title":"Ablative radioembolization of a synchronous renal cell carcinoma and hepatocellular carcinoma","volume":"34","author":"McGregor","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fonc.2017.00190","article-title":"The oncopig cancer model: an innovative large animal translational oncology platform","volume":"7","author":"Schachtschneider","year":"2017","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.nucmedbio.2024.108939_bb0040","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1084\/jem20210fta","article-title":"How Heidelberger and Avery sweetened immunology","volume":"202","author":"Van Epps","year":"2005","journal-title":"J Exp Med"},{"issue":"5416","key":"10.1016\/j.nucmedbio.2024.108939_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/244444a0","article-title":"Human\u00d7 mouse somatic cell hybrid clone secreting immunoglobulins of both parental types","volume":"244","author":"Schwaber","year":"1973","journal-title":"Nature"},{"issue":"5517","key":"10.1016\/j.nucmedbio.2024.108939_bb0050","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0055","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0076-6879(89)78034-4","article-title":"[32] Production and properties of chimeric antibody molecules","volume":"178","author":"Shin","year":"1989"},{"issue":"9","key":"10.1016\/j.nucmedbio.2024.108939_bb0060","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2967\/jnumed.122.263861","article-title":"Antibody engineering for nuclear imaging and radioimmunotherapy","volume":"63","author":"Rodriguez","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108939_bb0065","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","article-title":"Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation","volume":"13","author":"Jain","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0070","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1158\/1078-0432.CCR-04-0756","article-title":"The radioisotope contributes significantly to the activity of radioimmunotherapy","volume":"10","author":"D","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.nucmedbio.2024.108939_bb0075","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90\u2013labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"34","key":"10.1016\/j.nucmedbio.2024.108939_bb0080","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","article-title":"Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8","volume":"25","author":"Kramer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0085","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-009-0038-7","article-title":"Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma","volume":"97","author":"Kramer","year":"2010","journal-title":"J Neurooncol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108939_bb0090","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0969-8051(93)90037-U","article-title":"Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin","volume":"20","author":"Rosebrough","year":"1993","journal-title":"Nucl Med Biol"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108939_bb0095","first-page":"1045","article-title":"F (ab\u2032) 2 fragments versus intact antibody\u2014an isodose comparison","volume":"31","author":"Humm","year":"1990","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108939_bb0100","first-page":"1720","article-title":"Imaging and phase I study of 111In-and 90Y-labeled anti-LewisY monoclonal antibody B3","volume":"6","author":"Pai-Scherf","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.nucmedbio.2024.108939_bb0105","first-page":"1447","article-title":"Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma","volume":"1","author":"Mulligan","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108939_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-66","article-title":"Randomised phase I\/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma","volume":"9","author":"Sultana","year":"2009","journal-title":"BMC Cancer"},{"issue":"S4","key":"10.1016\/j.nucmedbio.2024.108939_bb0115","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cncr.24795","article-title":"Anti\u2013prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer","volume":"116","author":"Tagawa","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0120","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00259-012-2145-5","article-title":"Hepatic artery injection of 131 I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study","volume":"39","author":"Wu","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"22","key":"10.1016\/j.nucmedbio.2024.108939_bb0125","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial","volume":"118","author":"Ocean","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0130","first-page":"60","article-title":"Targeted therapy for metastatic prostate cancer with radionuclides","author":"Ahmadzadehfar","year":"2016","journal-title":"Prostate Cancer\u2013Leading\u2013Edge Diagnostic Procedures and Treatments"},{"issue":"10229","key":"10.1016\/j.nucmedbio.2024.108939_bb0135","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0140-6736(20)30164-1","article-title":"Small molecules, big impact: 20 years of targeted therapy in oncology","volume":"395","author":"Bedard","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.nucmedbio.2024.108939_bb0140","article-title":"Ambulatory same-day map-and-treat angiography for selective internal radiation therapy using a transradial approach","volume":"14","author":"Frost","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.nucmedbio.2024.108939_bb0145","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.tvir.2019.02.009","article-title":"Technical aspects and practical approach toward same-day Y90 radioembolization in the management of hepatocellular carcinoma","volume":"22","author":"Gabr","year":"2019","journal-title":"Tech Vasc Interv Radiol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2024.108939_bb0150","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1093\/jjco\/hyab107","article-title":"Debulking surgery for malignant tumors: the current status, evidence and future perspectives","volume":"51","author":"Hishida","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0155","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00259-019-04588-x","article-title":"The number of microspheres in Y90 radioembolization directly affects normal tissue radiation exposure","volume":"47","author":"Pasciak","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.nucmedbio.2024.108939_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-014-0048-0","article-title":"Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy","volume":"4","author":"H\u00f6gberg","year":"2014","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0165","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1007\/s00259-021-05340-0","article-title":"To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer","volume":"48","author":"Roosen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108939_bb0170","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jvir.2023.02.012","article-title":"Temporary vascular occlusion with retrievable microvascular plugs to protect normal liver during yttrium-90 radioembolization","volume":"34","author":"Pedersoli","year":"2023","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2024.108939_bb0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jvir.2015.01.029","article-title":"The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: a pilot study","volume":"26","author":"Pasciak","year":"2015","journal-title":"J Vasc Interv Radiol"},{"issue":"1 suppl","key":"10.1016\/j.nucmedbio.2024.108939_bb0180","first-page":"199S","article-title":"The promise of targeted \u03b1-particle therapy","volume":"46","author":"Mulford","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0185","first-page":"289","article-title":"With \u03b1-particle emitting radionuclides","volume":"48","author":"Zalutsky","year":"2004","journal-title":"QJ Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108939_bb0190","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jvir.2020.09.011","article-title":"Transarterial embolization of liver cancer in a transgenic pig model","volume":"32","author":"Nurili","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.nucmedbio.2024.108939_bb0195","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fonc.2017.00190","article-title":"The oncopig cancer model: an innovative large animal translational oncology platform","volume":"7","author":"Schachtschneider","year":"2017","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.nucmedbio.2024.108939_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239391","article-title":"Induction and characterization of pancreatic cancer in a transgenic pig model","volume":"15","author":"Boas","year":"2020","journal-title":"PLoS One"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:06:02Z","timestamp":1727298362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":40,"alternative-id":["S0969805124000659"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108939","relation":{},"ISSN":["0969-8051"],"issn-type":[{"type":"print","value":"0969-8051"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcatheter pseudo-vascular isolation for localization and concentration of a large molecule theranostic probe into a transgenic OncoPIG kidney tumor","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108939"}}